Evotec announces research agreement on fragment-based drug discovery with Cubist Pharmaceuticals

14-Jul-2009 - Germany

Evotec AG announced that it has entered into a research agreement with Cubist Pharmaceuticals, Inc..

Cubist will use Evotec’s proprietary fragment screening technology, EVOlutionTM to complement discovery research efforts in two of its antibacterials programs. EVOlutionTM combines biochemical, nuclear magnetic resonance (NMR) and surface plasmon resonance (SPR) screening technologies for the screening of low molecular weight compounds and fragments. By the combination of the orthogonal screening technologies, Evotec’s fragment screening platform is capable of screening a more diverse set of biological targets than other fragment screening approaches, as well as being able to screen the fragments in a high-throughput mode. The benefit of this is the ability to identify active fragments for numerous classes of biological targets in a short space of time.

In combination with fragment screening technology, Evotec will use its expertise in structural biology and protein crystallography in order to determine the 3-dimensional structure of the fragments bound to the targets of interest. To this end, Evotec will use its internal crystallography platform and will access the state-of-the-art synchrotron technology of the Diamond Light Source, its partner for protein crystallography. By providing this technology in combination with its fragment screening, Evotec will supply high quality results to Cubist to enable the structure-driven identification of drug candidates for their priority antibacterial targets.

No financial details are disclosed.

https://www.bionity.com/en/news/103289/evotec-announces-research-agreement-on-fragment-based-drug-discovery-with-cubist-pharmaceuticals.html